Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Artesunate (ART) has been indicated as a candidate drug for hepatocellular carcinoma (HCC). Glucosylceramidase (GBA) is required for autophagic degradation. Whether ART regulates autophagic flux by targeting GBA in HCC remains to be defined. Herein, our data demonstrated that the dramatic overexpression of GBA was significantly associated with aggressive progression and short overall survival times in HCC. Subsequent experiments revealed an association between autophagic activity and GBA expression in clinical HCC samples, tumor tissues from a rat model of inflammation-induced HCC and an orthotopic mouse model, and human HCC cell lines. Interestingly, probe labeling identified GBA as an ART target, which was further verified by both a glutathione-S-transferase pulldown assay and surface plasmon resonance analysis. The elevated protein expression of LC3B, the increased numbers of GFP-LC3B puncta and double-membrane vacuoles, and the enhanced expression of SQSTM1/p62 indicated that the degradation of autophagosomes in HCC cells was inhibited by ART treatment. Both the in vitro and in vivo data revealed that autophagosome accumulation through targeting of GBA was responsible for the anti-HCC effects of ART. In summary, this preclinical study identified GBA as one of the direct targets of ART, which may have promising potential to inhibit lysosomal autophagy for HCC therapy.
Abstract
Artesunate (ART) has been indicated as a candidate drug for hepatocellular carcinoma (HCC). Glucosylceramidase (GBA) is required for autophagic degradation. Whether ART regulates autophagic flux by targeting GBA in HCC remains to be defined. Herein, our data demonstrated that the dramatic overexpression of GBA was significantly associated with aggressive progression and short overall survival times in HCC. Subsequent experiments revealed an association between autophagic activity and GBA expression in clinical HCC samples, tumor tissues from a rat model of inflammation-induced HCC and an orthotopic mouse model, and human HCC cell lines. Interestingly, probe labeling identified GBA as an ART target, which was further verified by both a glutathione-S-transferase pulldown assay and surface plasmon resonance analysis. The elevated protein expression of LC3B, the increased numbers of GFP-LC3B puncta and double-membrane vacuoles, and the enhanced expression of SQSTM1/p62 indicated that the degradation of autophagosomes in HCC cells was inhibited by ART treatment. Both the in vitro and in vivo data revealed that autophagosome accumulation through targeting of GBA was responsible for the anti-HCC effects of ART. In summary, this preclinical study identified GBA as one of the direct targets of ART, which may have promising potential to inhibit lysosomal autophagy for HCC therapy.
참고문헌 (37)
- McGlynn, K. A., "Epidemiology of hepatocellular carcinoma", Hepatology, 73, pp.4~13 (2021)
- Lee, M. W., "Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma<3 cm : emphasis on association of local tumor progression and overall survival", Eur. Radiol, 30, pp.2391~2400 (2020)
- Vogel, A., "Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma", Cancer Treat. Rev, 82, pp.101946~ (2020)
- Mizushima, N., "Autophagy : renovation of cells and tissues", Cell, 147, pp.728~741 (2011)
- Mathew, R., "Autophagy suppresses tumorigenesis through elimination of SQSTM1", p62, 2009, pp.137, 1062~1075
- Towers, C. G., "Autophagy and cancer: modulation of cell death pathways and cancer cell adaptations", J. Cell Biol, 219, pp.e201909033~ (2020)
- Lan, S. H., "Autophagy suppresses tumorigenesis of hepatitis B virusassociated hepatocellular carcinoma through degradation of microRNA-224", Hepatology, 59, pp.505~517 (2014)
- Xue, S. T., "The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target", Autophagy, 16, pp.1823~1837 (2020)
- Song, J., "Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells", Autophagy, 5, pp.1131~1144 (2009)
- Chandramohan, K., "Autophagy: a potential therapeutic target of polyphenols in hepatocellular carcinoma", Cancers, 12, pp.562~ (2020)
- Dinur, T., "Human acid beta-glucosidase : isolation and amino acid sequence of a peptide containing the catalytic site", Proc. Natl Acad. Sci. USA, 83, pp.1660~1664 (1986)
- Dasari, S. K., "Signalome-wide RNAi screen identifies GBA1 as a positive mediator of autophagic cell death", Cell Death Differ, 24, pp.1288~1302 (2017)
- Du, T. T., "GBA deficiency promotes SNCA", α-synuclein accumulation through autophagic inhibition by inactivated PPP2A, 2015, pp.11, 1803~1820
- Zhou, X., "β-Glucosidase inhibition sensitizes breast cancer to chemotherapy", Biomed. Pharmacother, 91, pp.504~509 (2017)
- Li, Z., "Inhibition of β-glucosidase overcomes gastric cancer chemoresistance through inducing lysosomal dysfunction", Clin. Res. Hepatol. Gastroenterol, 45, pp.101456~ (2021)
- Zhang, Y., "Identification of β-glucosidase 1 as a biomarker and its high expression in hepatocellular carcinoma is associated with resistance to chemotherapy drugs", Biomarkers, 21, pp.249~256 (2016)
- Zhou, J., "Magnetically directed enzyme", prodrug prostate cancer therapy based on β-glucosidase, Int. J. Nanomed, pp.2020, 15[DOI]
- Adebayo, J. O., "Enhancing the antimalarial activity of artesunate", Parasitol. Res, 119, pp.2749~2764 (2020)
- Raffetin, A., "Use of artesunate in non-malarial indications", Med. Mal. Infect, 48, pp.238~249 (2018)
- Vandewynckel, Y. P., "Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent", Eur. J. Gastroenterol. Hepatol, 26, pp.861~870 (2014)
- Zhang, Y. Q., "A discovery of clinically approved formula FBRP for repositioning to treat HCC by inhibiting PI3K", AKT, Mol. Ther. Nucleic Acids, pp.2020, 19[DOI]
- Zhang, Y. Q., "Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms", Nanomedicine, 15, pp.86~97 (2018)
- Amaravadi, R., "Recent insights into the function of autophagy in cancer", Genes Dev, 30, pp.1913~1930 (2016)
- Huang, F., "Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma", World J. Gastroenterol, 24, pp.4643~4651 (2018)
- Klionsky, D. J., "Guidelines for the use and interpretation of assays for monitoring autophagy(3rd edition)", Autophagy, 12, pp.1~222 (2016)
- Wani, A., "Alborixin clears amyloid-β by inducing autophagy through PTENmediated inhibition of the AKT pathway", Autophagy, 15, pp.1810~1828 (2019)
- Mao, X., "Exploring and characterizing a novel combination of paeoniflorin and talatizidine for the treatment of rheumatoid arthritis", Pharmacol. Res, 153, pp.104658~ (2020)
- Guo, Q., "Biomolecular network-based synergistic drug combination discovery : a combination of paeoniflorin and liquiritin alleviates neuropathic pain by inhibiting neuroinflammation via suppressing the chemokine signaling pathway", Signal. Transduct. Target. Ther, 5, pp.73~ (2020)
- Wang, J., "Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum", Nat. Commun, 6, pp.10111~ (2015)
- Kriel, J., "The good, the bad and the autophagosome : exploring unanswered questions of autophagy-dependent cell death", Cell Death Differ, 26, pp.640~652 (2019)
- Yang, Z. J., "The role of autophagy in cancer: therapeutic implications", Mol. Cancer Ther, 10, pp.1533~1541 (2011)
- Andrade, T. M., "The role of chaperone-mediated autophagy in cell cycle control and its implications in cancer", Cells, 9, pp.2140~ (2020)
- Augustin, Y., "Artemisinins as a novel anti-cancer therapy: targeting a global cancer pandemic through drug repurposing", Pharmacol. Ther, 216, pp.107706~ (2020)
- Li, Z. J., "Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma", Acta Pharmacol. Sin, 42, pp.301~310 (2021)
- Jiang, Z., "Artesunate induces ER-derived-ROS-mediated cell death by disrupting labile iron pool and iron redistribution in hepatocellular carcinoma cells", Am. J. Cancer Res, 11, pp.691~711 (2021)
- Jing, W., "Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma", Biochem. Biophys. Res. Commun, 519, pp.41~45 (2019)
- Ilamathi, M., "Artesunate as an anti-cancer agent targets stat-3 and favorably suppresses hepatocellular carcinoma", Curr. Top. Med. Chem, 16, pp.2453~2463 (2016)